Nonclinical precedent Request an invite
Atlas/Oligonucleotides/Rytelo/Efficacy evidence

Rytelo: animal efficacy model or human cells?

imetelstat · Telomerase (oligo)
Efficacy evidence
Xenograft mice with ovarian cancer and AML cell lines and paediatric AML patient-derived cells
“In vivo, tumour growth inhibition and prolonged survival were demonstrated in xenograft mice models using cancer cell lines (ovarian cancer or AML cell lines) and patient-derived cancer cells (paediatric AML).”
✓ VerifiedEMA assessment report, p. 37Source ↗
Why that model
No MDS-specific cell lines or xenograft models; models of related myeloid and other tumors used
“Due to the lack of MDS specific cell lines and mouse xenograft models and given the increased expression of telomerase across most cancer types, particularly myeloid malignancies that are closely related to MDS, nonclinical data were generated in models of other tumor types that are relevant to demonstrate imetelstat’s mechanism of action and antitumor activity.”
✓ VerifiedFDA multi-discipline review, p. 44Source ↗
Reviewer's view of the efficacy data
EMA: no MDS-specific proof-of-concept; reliance on other myeloid malignancy models
“No specific proof-of concept for the proposed indication (MDS) is presented due to lack of MDS-specific cell lines and xenograft models”
✓ VerifiedEMA assessment report, p. 36Source ↗

Same question, other oligonucleotides

Amondys 45

casimersen · DMD exon 45 (PMO)
In vitro only: human rhabdomyosarcoma cells and normal primary myoblasts

Amvuttra

vutrisiran · TTR (siRNA)
hTTR V30M transgenic mice and cynomolgus monkeys: up to >=98% serum TTR reduction

Cyfendus

anthrax vaccine adsorbed, adjuvanted · TLR9 (CpG 7909 adjuvant)
Guinea pig and cynomolgus macaque lethal aerosolized B. anthracis spore challenge after two IM vaccinations

Dawnzera

donidalorsen · Prekallikrein / KLKB1 (ASO)
Mouse-specific surrogate ASO ISIS 482584 in five in vivo mouse vascular permeability studies

Defitelio

defibrotide · Fragmented DNA oligonucleotides
In vitro studies, primarily in a human microvascular endothelial cell line

Exondys 51

eteplirsen · DMD exon 51 (PMO)
Exon 51 skipping in human muscle cell cultures, DMD patient muscle explants, transgenic hDMD mice (IM) and cynomolgus monkey (IV)

Givlaari

givosiran · ALAS1 (siRNA)
Mouse and rat AIP disease models: givosiran prevented and reduced phenobarbital-induced ALA and PBG

Heplisav-B

hepatitis B vaccine (recombinant), adjuvanted · TLR9 (CpG 1018 adjuvant)
Anti-HBsAg immunogenicity of the adjuvanted vaccine in mice, rats and baboons

Izervay

avacincaptad pegol · C5 (aptamer)
In vitro and ex vivo complement functional assays plus in vivo complement inhibition in monkey

Kynamro

mipomersen · APOB (ASO)
Species-specific surrogate apoB ASOs in mouse, hamster, rabbit and monkey lipid models (mouse atherosclerosis models)

Leqvio

inclisiran · PCSK9 (siRNA)
PCSK9/LDL-C lowering in human PCSK9 transgenic mice and healthy NHPs

Macugen

pegaptanib · VEGF-165 (aptamer)
Mouse retinopathy of prematurity (hypoxia-induced retinal neovascularization), rat corneal pocket angiogenesis, guinea pig dermal permeability

Onpattro

patisiran · TTR (siRNA)
V30M/Hsf-1 KO mouse disease model (ALN-TTR01, same siRNA): 97-100% tissue TTR protein suppression

Oxlumo

lumasiran · HAO1 (siRNA)
Genetic PH1 mouse model (AGXT-/-): dose-dependent urinary oxalate reduction (~50% at 3 mg/kg)

Qalsody

tofersen · SOD1 (ASO)
Clinical molecule in transgenic human SOD1G93A mice and rats: SOD1 mRNA reduction; improved lifespan and rotarod in mouse

Qfitlia

fitusiran · Antithrombin / SERPINC1 (siRNA)
Hemophilia A and B knockout mice, genetic hemophilia A dog and antibody-induced hemophilia A monkey

Redemplo

plozasiran · APOC3 (siRNA)
Human ApoC-III transgenic (dyslipidemic) mouse, healthy cynomolgus monkey and dyslipidemic rhesus macaque

Rivfloza

nedosiran · LDHA (siRNA)
PH1 (Agxt knockout) and hydroxyproline-induced mouse models with mouse-active analog DCR-m355; LDHA knockdown in monkeys

Spinraza

nusinersen · SMN2 (ASO)
Transgenic SMA mouse models expressing human SMN2 (ICV and IT dosing)

Tegsedi

inotersen · TTR (ASO)
Transgenic mouse expressing human TTR Ile84Ser mutation and cynomolgus monkey (TTR mRNA/protein lowering)

Tryngolza

olezarsen · APOC3 (ASO)
Human apoC-III transgenic mice, wild-type CD-1 mice (mouse surrogate) and cynomolgus monkeys; primary hepatocytes in vitro

Viltepso

viltolarsen · DMD exon 53 (PMO)
DMD patient fibroblasts differentiated into myotubes: exon 53 skipping (EC50 0.63-2.3 µM) and dystrophin production

Vitravene

fomivirsen · CMV IE2 mRNA (ASO)
In vitro HCMV inhibition in primary human retinal pigment epithelial (RPE) cells

Vyondys 53

golodirsen · DMD exon 53 (PMO)
Rhabdomyosarcoma cells and immortalized and primary myoblasts from DMD patients; no in vivo exon 53 skipping study with golodirsen

Wainua

eplontersen · TTR (ASO)
Human mutant TTR (I84S) transgenic mice: hepatic hTTR mRNA and plasma TTR reduction

Waylivra

volanesorsen · APOC3 (ASO)
Fructose-fed hypertriglyceridemic rhesus monkeys dosed with volanesorsen (binding site 100% homologous)

Zanvastro

zilganersen · GFAP (ASO)
Transgenic mice overexpressing human GFAP (AxD-like features reduced); species surrogate ASO in rat AxD model

Summary across all 28 oligonucleotides →